lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== Further reading == Bates, H. E. (1946). The Tinkers of Elstow: the Story of the Royal Ordnance Factory run by J. Lyons and Company Limited for the Ministry of Supply for the World War of 1939–1945. Privately published, Bird, Peter J. (1994). LEO: the First Business Computer. Wokingham: Hasler Publishing Limited. ISBN 0-9521651-0-4. Bird, Peter (2000). The First Food Empire. A History of J. Lyons & Co. Phillmore. Chichester, West Sussex. ISBN 1-86077-132-7. Ferry, Georgina (2003). A Computer Called LEO. Lyons Teashops and the World's First Office Computer. Fourth Estate. London. ISBN 1-84115-185-8. (Published in United States 2004, Hammersmith: Harper Perennial. ISBN 1-84115-186-6.) Caminer, David, John Aris, Peter Hermon and Frank Land (eds). (1996, 1998). User-Driven Innovation (published in the United States as LEO: The incredible Story of the World's first Business Computer). McGraw Hill. ISBN 0-07-009501-9, Harding, Thomas (2019). Legacy : one family, a cup of tea and the company that took on the world. London: William Heinemann. ISBN 978-1785150890.
Asymmetric warfare – Araucanian leaders such as Lautaro developed effective military tactics to counter the Spanish invasion, winning the Arauco War. These tactics consisted in a combination of espionage, cattle raiding, and using attack waves in the battlefield to exhaust the enemy. Astronomy – Mesoamerican cultures, such as the Maya and Aztec, were able to accurately predict astronomical events, like eclipses, hundreds of years into the future. Atlatl – Paleo-Indians (Beringian Diaspora) from over 11,500 years ago had developed a highly developed spear thrower in the form of the atlatl to hunt woolly mammoths, giant sloths, mastodon, muskox (euceratherium), giant beaver, early caribou, steppe bison, saber-toothed cat, and other Pleistocene animals. Using the atlatl, these ancient Paleo-Indians were able to traverse much of the Americas from Alaska, down to Mexico, Central America, South America, and, finally, all the way south into Chile as they hunted and followed these Pleistocene megafauna within a short 3,000 year time period–from about 14,500 years ago to about 11,500 years ago. Avocado – Indigenous Americans were the first to domesticate and cultivate avocados.
=== R139w === One further single nucleotide polymorphism, found homozygous in 0% to 5% of different ethnic population, is leading to an amino acid exchange on position 139 from arginine to tryptophane. Furthermore, an alternative RNA splicing site is created leading to a loss of the quinone binding site. The variant protein of NQO1*3 has similar stability as its wild-type counterpart. The variation between the two is substrate specific and it has reduced activity for some substrates. It has been recently shown that the NQO1*3 polymorphism may also lead to reduced NQO1 protein expression.
Sources: en.wikipedia.org
== Life == Ogston was educated at Eton College and Balliol College, Oxford. Apart from a period as Freedom Research Fellow at the London Hospital, he spent most of his career at Oxford, being appointed Demonstrator (1938) and Reader (1955) in Biochemistry, and Fellow and Tutor in Physical Chemistry at Balliol (1937). In that capacity he had a major influence on other distinguished scientists, such as the Nobel prizewinner Oliver Smithies, who wrote his first paper with him, and Richard Dawkins, who chose to study zoology on his recommendation. In 1959 he took up an appointment as Professor of Physical Biochemistry at the John Curtin School of Medical Research at the Australian National University (ANU), Canberra, where he remained until 1970, when he returned to Oxford as President of Trinity College. On his retirement in 1978, he held visiting fellowships at the Institute for Cancer Research, Philadelphia and the John Curtin School of Medical Research, ANU. Ogston was elected FRS in 1955, and was awarded Lemberg Medal in 1970 and the Davy Medal in 1986.
== Etymology == The word muscle comes from Latin musculus, diminutive of mus meaning mouse, because the appearance of the flexed biceps resembles the back of a mouse. The same etymology is found in Greek, in which μῦς, mȳs, means both "mouse" and "muscle".
Sedatives and anxiolytics are used in sports like archery which require steady hands and accurate aim, and also to overcome excessive nervousness or discomfort for more dangerous sports. Diazepam, nicotine, and propranolol are common examples. Ethanol, the most commonly used substance by athletes, can be used for cardiovascular improvements though it has significant detrimental effects. Ethanol was formerly banned by WADA during performance for athletes performing in aeronautics, archery, automobile, karate, motorcycling, and powerboating but was taken off the ban list in 2017. It is detected by breath or blood testing. Cannabis is banned at all times for an athlete by WADA, though performance-enhancing effects have yet to be studied. Cannabis and nicotine are detected through urine analysis.
Sources: en.wikipedia.org
=== October === 1 October – In a televised address from Downing Street, Prime Minister Sir Keir Starmer condemns Iran's missile attack on Israel and says that Britain "stand[s] with Israel and ... [recognises] her right to self-defence in the face of this aggression". 2 October – Starmer makes his first visit to Brussels as prime minister, where he is attempting to rebuild UK–EU relations. It is reported that Starmer has repaid £6,000 in gifts and hospitality received since becoming prime minister. The Parliamentary Commission on Standards has launched an investigation into Labour peer Lord Alli over allegations of failing to register interests. 3 October – The UK announces that it will give up sovereignty of the Chagos Islands to Mauritius, subject to finalisation of a treaty. BBC presenter Laura Kuenssberg cancels a scheduled televised interview with Boris Johnson after accidentally sending him her briefing notes. Labour MP Kim Leadbeater announces plans to introduce a bill on assisted dying after earlier being selected to put forward a private member's bill. 4 October – GB News loses a High Court challenge against Ofcom in which it hoped to temporarily block the regulator from sanctioning it over its People's Forum programme featuring Rishi Sunak in February, while Sunak was prime minister. GB News is given permission to challenge the ruling, with Ofcom agreeing to hold off publication of its findings until the case is heard.
National teams April 29 – May 1: 2018 FIBA 3x3 Asia Cup in Shenzhen Men: Australia defeated Mongolia, 17–16, in the final. Japan took third place. Women: New Zealand defeated China, 14–11, in the final. Australia took third place. August 5 – 11: 2018 FIBA Under-18 Asian Championship in Thailand In the final, Australia defeated New Zealand, 73–62, to win their 1st title. China took third place. Note: All teams mentioned here, plus Philippines, have qualified to compete at the 2019 FIBA Under-19 Basketball World Cup. October 28 – November 3: 2018 FIBA Under-18 Women's Asian Championship in Bangalore China defeated Japan, 89–76, to win their fifth consecutive and 16th overall FIBA Under-18 Women's Asian Championship title. Australia took third place. Note: All teams mentioned here, plus South Korea, have qualified to compete at the 2019 FIBA Under-19 Women's Basketball World Cup. Clubs teams November 17, 2017 – May 2: 2017–18 ABL season San Miguel Alab Pilipinas defeated Mono Vampire, 3–2 in games played in a 5-legged final, to win their first ABL title. July 17 – 22: Summer Super 8 in Macau Guangzhou Long-Lions defeated Seoul Samsung Thunders, 78–72, to win their first title. Incheon Electroland Elephants took third place.
Enteroglucagon is a peptide hormone derived from preproglucagon. It is a gastrointestinal hormone, secreted from mucosal cells primarily of the colon and terminal ileum. It consists of 37 amino acids. Enteroglucagon is released when fats and glucose are present in the small intestine; which decrease the motility to allow sufficient time for these nutrients to be absorbed. In 1948, Sutherland and De Duve identified a gastrointestinal glucagon-like material in gastric mucosa, the term "enteroglucagon" was used to describe this material that shared a similar immunoreactivity with glucagon. A half-century later, Brubaker and Drucker studied proglucagon gene expression, they discovered the function of enteroglucagon is related to the growth of intestinal epithelium.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.